Literature DB >> 12844099

Clinical relevance of peripheral vascular occlusive disease in patients with rheumatoid arthritis and systemic lupus erythematosus.

Peter K Henke1, Pasu Sukheepod, Mary C Proctor, Gilbert R Upchurch, James C Stanley.   

Abstract

INTRODUCTION: Peripheral vascular occlusive disease (PVOD) and rheumatologic disease (RD) are common in older patients. The effect that coexistence of these diseases may have on patient health has not been rigorously investigated. The present study was undertaken in an attempt to characterize patients with PVOD plus RD in terms of inflammatory serologic disorders, medications, and procedures, and their relation to limb salvage.
METHODS: Medical records were reviewed retrospectively for all patients with diagnosed coexistent PVOD and non-arteritis RD treated over 15 years at the University of Michigan Hospital. Demographics, operative and medical therapies, and serologic studies were analyzed. Univariate and multivariate analysis and the Kaplan-Meier method were used to assess these variables in relation to limb salvage.
RESULTS: Forty-one patients (34 women, 7 men), with mean age of 67 years, were studied. Mean antinuclear antibody titer was 274, C-reactive protein concentration was 3.1 mg/mL, and sedimentation rate was 49. Twenty-nine percent of patients had claudication, 49% had rest pain, and 32% had tissue loss. Mean ankle brachial index was 0.55. Medications included nonsteroidal anti-inflammatory drugs (67% of patients), corticosteroids (54%), and specific immunosuppressive agents (27%). Operative therapy included aortofemoral bypass grafting (n = 4), infrainguinal bypass grafting (n = 14), embolectomy (n = 4), and primary amputation (n = 7). Overall 5-year limb salvage rate was 70% in patients undergoing bypass surgery. Comparison of surgical with nonsurgical patients showed no significant differences in baseline risk factors, serologic disorders, or anatomic location of vascular disease. Multivariate analysis revealed that rest pain and lack of immunosuppression were significantly predictive of need for revascularization or amputation (P <.05).
CONCLUSION: Patients with RD should receive treatment on the basis of standard criteria for limb ischemia, in that surgical revascularization outcomes are satisfactory. Immunosuppressive agents may confer a protective effect against progression of PVOD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12844099     DOI: 10.1016/s0741-5214(03)00074-0

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  5 in total

1.  Preliminary Report of Endovascular Treatment for Critical Limb Ischemia Patients with Connective Tissue Disease: Cases Series and Review of the Literature.

Authors:  Hideaki Obara; Kentaro Matsubara; Naoki Fujimura; Yasuhito Sekimoto; Yuko Kitagawa
Journal:  Int J Angiol       Date:  2015-06

2.  Sudden development of the upper and lower limb ischemia as the first manifestation of COVID-19 infection.

Authors:  Shafagh Aliasgarzadeh; AmirAhmad Arabzadeh; Sepideh Fathibitaraf; Mohammad Negaresh
Journal:  Int J Surg Case Rep       Date:  2022-06-21

3.  Lower limb arterial incompressibility and obstruction in rheumatoid arthritis.

Authors:  I del Rincón; R W Haas; S Pogosian; A Escalante
Journal:  Ann Rheum Dis       Date:  2004-07-22       Impact factor: 19.103

4.  Visualizing novel connections and genetic similarities across diseases using a network-medicine based approach.

Authors:  Brian Ferolito; Italo Faria do Valle; Kelly Cho; Hanna Gerlovin; Lauren Costa; Juan P Casas; J Michael Gaziano; David R Gagnon; Edmon Begoli; Albert-László Barabási
Journal:  Sci Rep       Date:  2022-09-01       Impact factor: 4.996

Review 5.  Evaluation of the Risk of Getting Peripheral Artery Disease in Rheumatoid Arthritis and the Selection of Appropriate Diagnostic Methods.

Authors:  Surik Sedrakyan; Tehreem Fatima; Mst Khaleda Khatun; Muhammad R Awan; Nkechi A Okam; Nusrat Jahan
Journal:  Cureus       Date:  2020-08-16
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.